Are you a healthcare provider?
This site is intended for U.S. healthcare providers only.
By clicking YES, you attest you are a healthcare provider licensed in the U.S.
Fast administration time from preparation to injection
Easy to use during preparation
PREFILLED SYRINGE: No reconstitution required. The syringe is ready to inject, which can help reduce preparation time.
LOW-VOLUME: The injection volume of Somatuline Depot is 0.5 mL.
*From preparation to injection.
PRESTO=The PREference STudy of lanreOtide autogel.
When it comes to Somatuline Depot, delivery matters. That’s why the Somatuline Depot syringe was redesigned with patients, caregivers, and healthcare providers taking part in the process (see the “Updated Somatuline Depot Syringe Study Design” information below). Offering a prefilled dose, sturdy plunger, and needle safety system, the redesigned syringe can help improve the monthly injection process.
PREFILLED SYRINGE with no reconstitution required. The syringe is ready to inject, which can help reduce preparation time.
TRANSPARENT BODY for visual confirmation of delivery.
NEEDLE SAFETY SYSTEM to help minimize the risk of needle-stick injuries.
LOW-VOLUME injection of 0.5 mL.
The Somatuline Depot delivery system was updated in response to feedback, provided by nurses, and caregivers, during 4 formative studies regarding the design and functionality of updated delivery device prototypes. The subsequent human factors validation study in 2017 reviewed the use of the updated delivery system by intended users in the intended use environment. Most common errors among HCPs (N=35) were failure to follow correct procedure if the syringe was dropped (34%) and failure to inspect the product before administration (34%); no task errors were specific to the delivery system. Key changes between the previously marketed delivery system and the updated delivery system are: an overcap to improve the ergonomics (and needle shield removal); plunger support for the updated delivery system; and an improved version of the needle safety system.
Watch a video about how to use the redesigned syringe.
To report SUSPECTED ADVERSE REACTIONS, contact Ipsen Biopharmaceuticals, Inc. at 1-855-463-5127 or FDA at 1-800-FDA-1088 or www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program.